| Parameter | Acceptable | Optimal |
|--------------------------|---|--|
| Indication | Adults at risk of invasive <i>E. coli</i> | Adults at risk of invasive E. coli |
| | infections or pregnant women | infections and E. coli UTI |
| Target Demographic | >65 yoa, pregnant women* | All ages and pregnant women* |
| Presentation | Single-dose vial, liquid | Single-dose vial, lyophilized |
| Dose Regimen | Two doses IV, one week apart | One dose IV |
| Human Dose | TBD | TBD, predictable PK |
| Safety Profile | Limited local side effects, limited | No local side effects, no antidrug |
| | antidrug antibody response | antibody response |
| Efficacy | >90% | >95% |
| Durability of Protection | One month, incl neonatal sepsis | One year |
| Coverage | >80% of globally clinically | >90% of globally clinically |
| | relevant E. coli isolates including | relevant <i>E. coli</i> isolates including |
| | >90% drug-resistant strains | >99% of drug-resistant strains |
| Stability | 18 months at 2-8°C | Three years at 2-8°C |
| Contraindications | - | - |
| Marketing Attributes | COGs acceptable in LMIC | COGs acceptable in LMIC |

^{*}Maternal immunization to protect against neonatal sepsis